CN Bio adds computational modeling capabilities to ADME services for enhanced bioavailability profiling
New PhysioMimix in silico tools unlock deeper functional insights from existing assays, advancing translation of MPS data to predict human ADME behaviorEnd-to-end support from experimental design to data interpretationCambridge, UK, 02 Septembe
CN Bio introduces cross-species DILI services to enhance in vitro to in vivo extrapolation during preclinical drug development
CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, has introduced two new animal microphysiological system (MPS) models that enhance translatability in preclinical drug safety and toxicology assessments to its C
CN Bio expands access to OOC solutions for APAC customers with distributor agreement in South Korea
Partnership with SCINCO strengthens international sales and technical support channels in key region as part of ongoing global expansion
CN Bio and Pharmaron establish long-term strategic partnership to develop OOC technologies on a global R&D platform
Partnership to validate and promote the application of CN Bio’s PhysioMimix technology, with future opportunities for novel application and assay development
CN Bio launches PhysioMimix DILI assay kit: Human 24, for enhanced preclinical toxicology testing
· All-in-one kit enables in-house, in vitro profiling of human drug-induced liver injury
CN Bio signs strategic partnership with Primetech Corporation to establish distribution channel for OOC solutions in Japan
Agreement establishes direct distribution channel for customers in Japan, providing local support and expertise Partnership solidifies CN Bio’s presence in Asian markets and supports ongoing global expansionCambridge, UK, 14 January 2025:
CN Bio launches PhysioMimix Bioavailability assay kit: Human 18
Unique solution enabling researchers to profile human oral drug bioavailability in vitro, in their own laboratories Expands access to CN Bio’s robust multi-organ Gut/Liver-on-a-chip model to accelerate and de-risk clinical progression of drug candidatesCN Bio appoints Lydia Seymour as VP People and Culture to further strengthen leadership team
Key appointment to support continued UK and US team expansionCambridge, UK, 27: CN Bio, a leading provider of single- and multi-organ microphysiological systems, announces the appointment of Lydia Seymour as Vice President of People and Cultur
CN Bio raises $21 million USD in first close of Series B investment round
Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10M and $5.5M, respectively Investment will expand product development and scaling of the organization to meet increased demand for Organ-on-a-Chip (OOC) solutionsCambridge,
CN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies
Cambridge, UK, and Durham, North Carolina, US - CN Bio and Altis Biosystems, Inc., leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, announces a strategic partnership.
CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing
PhysioMimix NASH assay used to provide human-relevant data on compound efficacy for Inipharm’s lead candidate, INI-822 Submission represents first example of an OOC provider’s data supporting clinical progression of a drug for metabolic, fibrotic liver diseaseCN Bio wins ‘Most Impactful Industry Collaboration of the Year’ at the OBN Awards 2023 for ongoing research with the FDA
Six-year collaboration recognised at prestigious awards ceremony for its continued success in advancing OOC research to support widespread adoption across the pharmaceutical industry.
CN Bio appoints Neil Rumbelow as Director of Product Development
Key senior appointment to drive research and development activities for portfolio of PhysioMimix OOC microphysiological systems
CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems
Cambridge, UK - CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), and LifeNet Health LifeSciences, “LifeNet Health”, a non-profit, global leader in all-human research solutions, announces a strategic partnership to supply validated primary human cells for use with CN Bio’s PhysioMimix® OOC range of MPS.
CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer
Cambridge, UK, 30th August 2023: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the appointment of Dr. Tomasz Kostrzewski as Chief Scientific Officer.
CN Bio appoints Dr. Samantha Macro as Chief Financial Officer
Key executive appointment provides extensive financial industry experience as the Company implements ambitious global growth strategy
CN Bio appoints Deepak Singh as Vice President of Sales and Marketing
Key appointment as company seeks to continue global expansion of microphysiological systems and contract research service offerings.
CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System
Cambridge, UK - CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), announces the commercial launch of the PhysioMimix™ Single-organ Higher Throughput (HT) System.
The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced that the U.S.
CN Bio appoints Dr Paul Brooks as Chief Executive Officer
Key strategic appointment as the Company enters next phase of commercial growth and global expansion of its products and services Former CEO, Dr David Hughes, appointed to Scientific Advisory BoardCambridge, UK, 19 December 2022:
CN Bio’s PhysioMimix™ Multi-Organ Microphysiological System selected by The Scientist as a ‘Top 10 Innovation 2021’
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), has been recognised by The Scientist for developing a Top 10 Innovation of 2021. This year’s list includes CN Bio’s PhysioMimix™ Multi-Organ MPS; a next-generation OOC platform that provides advanced insights into the potential effects of novel therapeutics that…
CN Bio and iiCON announce COVID-19 research collaboration
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced a research collaboration with the Infection Innovation Consortium (iiCON), a global collaborative infectious disease R&D programme, to validate the next generation of COVID-19 research tools.
CN Bio expands service offering to support oncology drug discovery
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced the commercial launch of its Oncology Service in response to the global need to improve cancer drug discovery approval rates.
CN Bio licenses human gut microbiome modelling tool from MIT and Northeastern University
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), announced it has secured the licensing rights to a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and Northeastern University.
Lonza and CN Bio announce distribution agreement
Basel, Switzerland and Cambridge, UK...– Lonza and CN Bio have entered into a distribution agreement whereby Lonza will supply a selection of hepatic cells to be prequalified by CN Bio for use in their PhysioMimixTM Single-and Multi-Organ MPS to transform the way human-relevant pre-clinical data is generated.